CD26: a surface protease involved in T-cell activation

doi:10.1016/0167-5699(94)90316-6

Immunology Today

Volume 15, Issue 4, April 1994, Pages 180-184

Immunology Today

https://doi.org/10.1016/0167-5699(94)90316-6 Get rights and content

Abstract

CD26 is a proteolytic enzyme (dipeptidylpeptidase IV) with a wide tissue distribution and a unique specificity. Recent developments indicate that CD26 is a multifunctional molecule that may have important functions in the immune system. Here, Bernhard Fleischer reviews the current knowledge of CD26 and discusses the possible functions of this molecule in T lymphocytes.

References (45)

M. Hegen et al.
Cell. Immunol.
(1993)
D. Marguet et al.
J. Biol. Chem.
(1992)
S. Ogata et al.
J. Biol. Chem.
(1989)
D. Darmoul et al.
J. Biol. Chem.
(1992)
C. Tiruppathi et al.
J. Biol. Chem.
(1990)
T. Kato et al.
Biochim. Biophys. Acta
(1978)
T. Mattern et al.
Immunobiology
(1993)
M. Hegen et al.
Immunobiology
(1993)
A. Yaron et al.
Crit. Rev. Biochem. Mol. Biol.
(1993)
H. Stein et al.

D.A. Fox et al.

J. Immunol.

(1984)

B. Fleischer

J. Immunol.

(1987)

B. Fleischer et al.

Eur. J. Immunol.

(1986)

M. Plana et al.

Eur. J. Immunol.

(1991)

C. Morimoto et al.

J. Immunol.

(1989)

P. Naquet et al.

Immunol. Rev.

(1989)

L.A. Bristol et al.

J. Immunol.

(1992)

S. Hartel-Schenk et al.

Eur. J. Biochem.

(1991)

T. Tanaka et al.

J. Immunol.

(1992)

M. Hegen et al.

J. Immunol.

(1990)

K.H. Enssle et al.

Clin. Exp. Immunol.

(1990)

D.A. Hafler et al.

J. Immunol.

(1986)

Cited by (59)

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
2020, Diabetes Research and Clinical Practice
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19.
It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a plausible approach to mitigate COVID-19.
Linagliptin attenuates chronic post-ischemia pain: Possible anti-inflammatory and anti-oxidant mechanisms
2018, European Journal of Pharmacology
Citation Excerpt :
The beneficial effects of DPP-4 inhibitors could primarily be due to their beneficial effects on blood glucose levels and impaired insulin signaling in various cells, however, other mechanisms also exist. DPP-4, which is identical to CD26, may potentiate inflammation via the catalytic and non-catalytic function (Fleischer, 1994; Ta et al., 2011). Specifically, the non-catalytic function of DPP4 is essential in the regulation of T cell activation (Ohnuma et al., 2008) and modulation of the inflammatory processes.
Complex regional pain syndrome (CRPS) is a debilitating neurologic disorder with an interlinked and yet incompletely defined pathogenesis. Treatment options remain a therapeutic challenge. Linagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which are used for the treatment of diabetes mellitus. Apart from the improvement of glycemic control, accumulating evidence points to the beneficial effects of DPP-4 inhibitors in a wide array of conditions. Herein, the present study was outlined to investigate the antinociceptive effect of linagliptin in acute pain conditions, and in an animal model of CRPS.
A prolonged hind paw ischemia reperfusion (I/R) injury to the left hind paw was done to induce chronic post-ischemia pain (CPIP) in rats. Allodynia and hyperalgesia were assessed in both ipsilateral and contralateral hind paws at different time points. At the end of the experiment, markers of oxidative stress and inflammatory cytokines were assayed in paw skin samples.
The results showed that linagliptin had no effect on acute nociception. On the other hand, linagliptin treatment, for seven days, ameliorated hyperalgesia, mechanical and cold allodynia, and attenuated oxidative and inflammatory markers in CPIP rats.
In conclusion, linagliptin was able to ameliorate aberrant pain behavior induced by prolonged hind paw ischemia. These effects can be attributed, at least partially, to the reduction of inflammatory cytokine levels and restore oxidant/antioxidant balance in the CPIP model. Hence, linagliptin pleiotropic effects open a new horizon to further investigate its role in the treatment of inflammatory and chronic painful conditions, especially in diabetic patients.
DPPIV/CD26 as a target in anti-inflammatory therapy
2017, Immunity and Inflammation in Health and Disease: Emerging Roles of Nutraceuticals and Functional Foods in Immune Support
Dipeptidyl peptidase IV (DPPIV/CD26) is an enzyme involved in glucose homeostasis and it is the therapeutic target of the so-called gliptins in type 2 diabetes. However, the function of this enzyme reaches much further, and through its substrate cleavage and interactions it can play a role in the immune system. The available (pre-)clinical data on the therapeutically used DPPIV/CD26-inhibitors in inflammatory diseases such as type 1 diabetes, psoriasis and rheumatoid arthritis are discussed here. We also look into several naturally occurring DPPIV/CD26-inhibitors and review whether these can be of additional value next to conventional therapy as a functional food or nutraceutical.
The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia
2016, Leukemia Research
A number of factors related to B-cell chronic lymphocytic leukemia (B-CLL) patients' prognosis have been identified. However, still some factors better reflecting disease activity in individual cases are explored. The study aimed to evaluate prognostic significance of dipeptidylpeptidase IV/CD26 expression on B-CLL cells and its relationship with other well established prognostic factors. The study included 94 patients with newly diagnosed B-CLL and involved analysis of clinical, laboratory, flow-cytometry and cytogenetic data. Detailed analysis showed that CD26 expression on B-CLL cells correlates with Rai’s clinical stage of the disease at diagnosis (p = 0.034), β2-microglobulin concentration (p = 0.012), lactic acid dehydrogenase activity (p = 0.045) and absolute lymphocytes’ count (p = 0.027) in the blood. The multivariate analysis revealed that time to treatment (TTT) was significantly influenced by Rai clinical stage, LDH activity in blood and CD26 expression on B-CLL cell’s. Moreover, in the multivariate analysis restricted to the group of patients with documented cytogenetic risk (n = 36) CD26 expression, Rai clinical stage and cytogenetic profile remained their independent impact on TTT. The results of our study indicate that the CD26 expression should be incorporated in B-CLL patients risk assessment along with well known prognostic factors, since it seems to have a relationship with the tumor mass and influences TTT.
Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
2016, Biochemical and Biophysical Research Communications
Dipeptidyl peptidase (DPP)-4 plays an important role in endothelial cell biology. We have shown that the DPP-4 inhibitor Linagliptin can inhibit the endothelial-mesenchymal transition (EndMT) and ameliorate diabetic kidney fibrosis associated with the suppression of DPP-4 protein levels via the induction of miR-29. The current study demonstrated that such effects of Linagliptin on endothelial cell profibrotic programs were drug-specific but not class effects. In the cell-free system, both Linagliptin and Sitagliptin inhibited recombinant DPP-4 activity in a concentration-dependent manner. Linagliptin can inhibit all of the following: DPP-4 activity and protein level, integrin β1 protein levels, EndMT, and DPP-4 3′UTR activity; Sitagliptin, however, inhibited none of these in the current study. Additionally, TGF-β2 induced both the induction of VEGF-R1 and the suppression of VEGF-R2 levels in endothelial cells, and both were inhibited by Linagliptin but not by Sitagliptin. miR-29, the miR that negatively regulates the 3′UTR of DPP-4 mRNA, was suppressed by TGF-β2 and restored by Linagliptin but not by Sitagliptin. Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. In conclusion, each of the DPP-4 inhibitors may have unique drug-specific effects.
Purification, identification and structural modelling of DPP-IV inhibiting peptides from barbel protein hydrolysate
2016, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Inhibition of DPP-IV may improve glycemic control in diabetics by preventing the rapid breakdown and there by prolonging the physiological action of incretin hormones. Barbel muscle protein hydrolysate (BMPH) was noted to exhibit DPP-IV inhibitory activity, with an IC₅₀ value of 1.94 mg/mL. It was fractionated into five major fractions (F_I–F_V) by size exclusion chromatography using a Superdex peptide. The F_III fraction was noted to display the highest inhibitory activity, with an IC₅₀ value of 1.23 mg/mL, and was, therefore, further fractionated by RP-HPLC. Four major peptide sub-fractions were selected. The results revealed that the SF₄ sub-fraction showed the highest DPP-IV inhibitory activity, with an IC₅₀ value of 0.21 mg/mL. This sub-fraction was submitted to RP-HPLC, ESI–MS, and ESI–MS/MS analyses. The findings indicated that SF4 consisted of two peptides (IC₅₀ = 96 μg/mL), namely PP1 and PP2, whose structures were identified as Trp-Ser-Gly (330 Da) and Phe-Ser-Asp (349 Da), respectively. This is the first report of these sequences from barbel proteins.
The structural modelling through docking simulations results with DPP-IV showed that the Trp-Ser-Gly peptide bound to DPP-IV with high affinity. Overall, the results suggested that BMPH can be considered as a promising natural source of DPP-IV inhibitory peptides.

View all citing articles on Scopus

View full text

ReviewCD26: a surface protease involved in T-cell activation

Abstract

Cell. Immunol.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Biochim. Biophys. Acta

Immunobiology

Immunobiology

Crit. Rev. Biochem. Mol. Biol.

J. Immunol.

J. Immunol.

Eur. J. Immunol.

Eur. J. Immunol.

J. Immunol.

Immunol. Rev.

J. Immunol.

Eur. J. Biochem.

J. Immunol.

J. Immunol.

Clin. Exp. Immunol.

J. Immunol.

Review
CD26: a surface protease involved in T-cell activation